TY - JOUR
T1 - Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan
AU - Fuji, T.
AU - Wang, C. J.
AU - Fujita, S.
AU - Kawai, Y.
AU - Kimura, T.
AU - Tachibana, S.
N1 - Publisher Copyright:
© 2014 The Authors.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000. IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.
AB - Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip arthroplasty (THA) patients randomly received edoxaban 15 or 30 mg once daily or enoxaparin 2000. IU (20-mg) twice daily for 11-14 days. Thromboembolic event incidences were 3.8% (3/78), 2.8% (2/72), and 4.1% (3/74) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Edoxaban-induced prolongation of prothrombin time, international normalized ratio, and activated partial thromboplastin time were proportional to plasma edoxaban concentration. Major or clinically relevant non-major bleeding incidences were 2.2% (2/89), 1.2% (1/85), and 2.3% (2/87) for edoxaban 15-mg, 30-mg, and enoxaparin, respectively (P= 1.00). Once-daily edoxaban showed similar efficacy and safety to enoxaparin for prevention of thromboembolic events in patients undergoing THA.
KW - Edoxaban
KW - Enoxaparin
KW - Factor Xa inhibitor
KW - Thromboembolic events
KW - Total hip arthroplasty
UR - http://www.scopus.com/inward/record.url?scp=84912535162&partnerID=8YFLogxK
U2 - 10.1016/j.arth.2014.05.029
DO - 10.1016/j.arth.2014.05.029
M3 - 文章
C2 - 25047458
AN - SCOPUS:84912535162
SN - 0883-5403
VL - 29
SP - 2439
EP - 2446
JO - Journal of Arthroplasty
JF - Journal of Arthroplasty
IS - 12
ER -